Modeling oncolytic virotherapy: is complete tumor-tropism too much of a good thing?
From MaRDI portal
Publication:2415663
DOI10.1016/j.jtbi.2014.04.030zbMath1412.92158OpenAlexW2023793534WikidataQ42219809 ScholiaQ42219809MaRDI QIDQ2415663
Kenichi W. Okamoto, Priyanga Amarasekare, Ian T. D. Petty
Publication date: 23 May 2019
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jtbi.2014.04.030
Related Items (8)
Bistability in a model of tumor-immune system interactions with an oncolytic viral therapy ⋮ On a mathematical model of tumor-immune system interactions with an oncolytic virus therapy ⋮ The role of tumor activation and inhibition with saturation effects in a mathematical model of tumor and immune system interactions undergoing oncolytic viral therapy ⋮ Analysis of a delayed and diffusive oncolytic M1 virotherapy model with immune response ⋮ Global dynamics of reaction-diffusion oncolytic M1 virotherapy with immune response ⋮ A mathematical model that combines chemotherapy and oncolytic virotherapy as an alternative treatment against a glioma ⋮ Computation of the conditions for anti-angiogenesis and gene therapy synergistic effects: sensitivity analysis and robustness of target solutions ⋮ Modeling the virus-induced tumor-specific immune response with delay in tumor virotherapy
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response
- Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions
- Modeling and analysis of a virus that replicates selectively in tumor cells
- Biological stoichiometry of tumor dynamics: Mathematical models and analysis
- ODE models for oncolytic virus dynamics
- Modeling of cancer virotherapy with recombinant measles viruses
- The competitive dynamics between tumor cells, a replication-competent virus and an immune response
This page was built for publication: Modeling oncolytic virotherapy: is complete tumor-tropism too much of a good thing?